Magdalena Gawron-Kiszka

Dr. Magdalena Gawron-Kiszka

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
MTMaciej Tomaszewski
Maciej Tomaszewski
FCFadi Charchar
Fadi Charchar
TBTimothy Barnes
Timothy Barnes
MGMagdalena Gawron-Kiszka
Magdalena Gawron-Kiszka
ASAgnieszka Sedkowska
Agnieszka Sedkowska
EZEwa Zukowska-Szczechowska
Ewa Zukowska-Szczechowska
Objective— A rare mutation in low-density lipoprotein receptor-related protein 6 gene (LRP6) was identified as the primary molecular defect underlying monogenic form of coronary artery disease. We hypothesized that common variants in LRP6 could predispose subjects to elevated LDL-cholesterol (LDL-C). Methods and Results— Twelve common (minor allele frequency ≥0.1) single nucleotide polymorphisms in LRP6 were genotyped in 703 individuals from 213 Polish pedigrees (Silesian Cardiovascular Study families). The family-based analysis revealed that the minor allele of rs10845493 clustered with elevated LDL-C in offspring more frequently than expected by chance ( P =0.0053). The quantitative analysis restricted to subjects free of lipid-lowering treatment confirmed the association between rs10845493 and age-, sex-, and BMI-adjusted circulating levels of LDL-C in families as well as 2 additional populations − 218 unrelated subjects from Silesian Cardiovascular Study replication panel and 1138 individuals from Young Men Cardiovascular Association cohort ( P =0.0268, P =0.0476, and P =0.0472, respectively). In the inverse variance weighted meta-analysis of the 3 populations each extra minor allele copy of rs10845493 was associated with 0.14 mmol/L increase in age-, sex-, and BMI-adjusted LDL-C (SE=0.05, P =0.0038). Conclusions— Common polymorphism in the gene underlying monogenic form of coronary artery disease impacts on risk of LDL-C elevation.

6 January 2016 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
JBJessica Becker
Jessica Becker
SHStephan L Haas
Stephan L Haas
AMAnna Mokrowiecka
Anna Mokrowiecka
JWJustyna Wasielica-Berger
Justyna Wasielica-Berger
ZAZeeshan Ateeb
Zeeshan Ateeb
JSJohannes Schumacher
Johannes Schumacher
Idiopathic achalasia is a severe motility disorder of the esophagus and is characterized by a failure of the lower esophageal sphincter to relax due to a loss of neurons in the myenteric plexus. Most recently, we identified an eight-amino-acid insertion in the cytoplasmic tail of HLA-DQβ1 as strong achalasia risk factor in a sample set from Central Europe, Italy and Spain. Here, we tested whether the HLA-DQβ1 insertion also confers achalasia risk in the Polish and Swedish population. We could replicate the initial findings and the insertion shows strong achalasia association in both samples (Poland P=1.84 × 10−04, Sweden P=7.44 × 10−05). Combining all five European data sets – Central Europe, Italy, Spain, Poland and Sweden – the insertion is achalasia associated with Pcombined=1.67 × 10−35. In addition, we observe that the frequency of the insertion shows a geospatial north–south gradient. The insertion is less common in northern (around 6–7% in patients and 2% in controls from Sweden and Poland) compared with southern Europeans (~16% in patients and 8% in controls from Italy) and shows a stronger attributable risk in the southern European population. Our study provides evidence that the prevalence of achalasia may differ between populations.

1 December 2017
Verified
Journal Article
Closed access
ABA Budzynska
A Budzynska
MGMagdalena Gawron-Kiszka
Magdalena Gawron-Kiszka
ENE Nowakowska-Dulawa
E Nowakowska-Dulawa
JSJ Spiewak
J Spiewak
MLM Lesinska
M Lesinska
MHM Hartleb
M Hartleb

Verified
Journal Article
Open access
PDF file
PBPéter Bacsur 
Péter Bacsur 
SNSylwia Nemeczek
Sylwia Nemeczek
RFRafał Filip
Rafał Filip
FFFotios S. Fousekis
Fotios S. Fousekis
KMKonstantinos Mpakogiannis
Konstantinos Mpakogiannis
TMTamás Molnár
Tamás Molnár
Background: Crohn’s disease complicated by intra-abdominal abscesses often requires surgery. Percutaneous drainage may prevent surgery, but optimal post-drainage management is unclear. We aimed to analyze the long-term outcomes of Crohn’s disease with intra-abdominal abscesses after intervention. Methods: Patients with penetrating Crohn’s disease and a single intra-abdominal abscess were enrolled in this multicenter, international, retrospective study after the detection of the abscess (baseline), with a minimum follow-up of 12 months. Those requiring urgent bowel resection were excluded. Patients were grouped by elective surgical need after successful (catheter insertion with effective drainage) percutaneous drainage (controls: no pre-resection drainage). The primary outcome was abscess recurrence. We also assessed stoma rate, post-procedural complications, hospitalizations, advanced treatment need, postoperative luminal recurrence, and need for re-drainage. Results: We studied 157 patients with Crohn’s disease (9 countries; males: 58%, median age: 32.4 [interquartile range: 25–39 years]); 89/157 underwent percutaneous drainage (median follow-up: 95.9 weeks [interquartile range: 58–104]). Abscess recurrence did not differ by drainage (p = 0.221). Abscess size was associated with advanced-treatment initiation (Odds ratio: 0.978; 95% confidence interval: 0.960–0.997, p = 0.023) and postoperative luminal recurrence (Odds ratio: 1.044, 95% confidence interval: 1.012–1.078, p = 0.007). Time to resection was longer after drainage, and ROC analysis raised predictive value for re-drainage (16.6 weeks post-drainage; AUC = 0.82, 95% confidence interval: 0.73–0.92). Patients without drainage had more post-procedural complications. Conclusions: Abscess size should guide management. Delayed resection may increase re-drainage odds, whereas surgery alone may have higher complication rates. Percutaneous drainage can safely postpone resection.

1 January 2026 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
AMAgata Michalak
Agata Michalak
IZIwona Zawada
Iwona Zawada
ADAnna Deskur
Anna Deskur
MKMaria Kopertowska-Majchrzak
Maria Kopertowska-Majchrzak
Renata Talar-WojnarowskaRenata Talar-Wojnarowska
Renata Talar-Wojnarowska
HCHalina Cichoz-Lach
Halina Cichoz-Lach
Background: Inflammatory bowel disease (IBD) encompasses chronic gastrointestinal disorders that significantly impact patients’ quality of life (QoL). While clinical trials support the efficacy and safety of vedolizumab, real‐world data linking its effectiveness to QoL‐related patient‐reported outcomes remain limited. This prospective observational study assessed the effects of 14‐week vedolizumab induction therapy on QoL (i.e., fatigue, mood, and sleep disturbances), clinical response, safety, and predictors of response. Methods: A total of 257 patients with ulcerative colitis (UC; n = 205) and Crohn’s disease (CD; n = 52) received 14‐week vedolizumab induction therapy. Disease activity, QoL (assessed using the total Inflammatory Bowel Disease Questionnaire [IBDQ]), fatigue (Functional Assessment of Chronic Illness Therapy‐Fatigue [FACIT‐Fatigue]), mood and sleep disturbances (PROMIS Depression and Sleep Disturbance scales), and selected biomarkers were evaluated. Clinical response was assessed using the Mayo score for UC and Crohn’s Disease Activity Index (CDAI) score for CD. Results: At Week 14, clinical response was observed in 82% of UC patients and 82.7% of CD patients. Median total IBDQ scores increased by 45.0 points in UC and 31.5 points in CD ( p < 0.001). Median prorated FACIT‐Fatigue scores increased by 5.0 points in both groups ( p < 0.001), while median prorated PROMIS Sleep Disturbance and Depression T‐scores decreased ( p < 0.05). Improvement in QoL was moderately correlated with clinical response ( r = 0.5). In logistic regression analysis, baseline patient characteristics indicative of advanced disease were associated with a reduced likelihood of clinical and QoL response to treatment. A total of 28 adverse events were reported, including 11 serious events and four treatment‐related events. Conclusions: Vedolizumab reduced disease activity and led to a rapid improvement in QoL during the 14‐week induction therapy in patients with IBD. Clinical response was positively correlated with QoL improvement. Predictors of reduced response were consistent with features of advanced disease.